Christopher J Lord

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 19

Top Venues

Cancer research

Oncogene

Nature genetics

Science (New York, N.Y.)

Institute of Cancer Research

University of Surrey (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Institute of Cancer Research Jul 1o 2017

United Kingdom

Professor of Cancer Genomics

Education History

University of Surrey Sep 1o 1989 - Jul 1o 1993

United Kingdom

BSC :: Biochemistry

Publications

Colm J Ryan, Lovely Paul Solomon Devakumar, Stephen J Pettitt, Christopher J Lord
Complex synthetic lethality in cancer. Nature genetics (2023)
Stephen J Pettitt, Nan Shao, Diana Zatreanu, Jessica Frankum, Ilirjana Bajrami, Rachel Brough, Dragomir B Krastev, Theodoros I Roumeliotis, Jyoti Sharma Choudhary, Sonja Lorenz, Alistair Rust, Johann S de Bono, Timothy Anthony Yap, Andrew N J Tutt, Christopher J Lord
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant. Oncogene (2023)
Philip Bland, Harry Saville, Patty T Wai, Lucinda Curnow, Gareth Muirhead, Jadwiga Nieminuszczy, Nivedita Ravindran, Marie Beatrix John, Somaieh Hedayat, Holly E Barker, James Wright, Lu Yu, Ioanna Mavrommati, Abigail Read, Barrie Peck, Mark Allen, Patrycja Gazinska, Helen N Pemberton, Aditi Gulati, Sarah Nash, Farzana Noor, Naomi Guppy, Ioannis Roxanis, Guy Pratt, Ceri E Oldreive, Tatjana Stankovic, Samantha Barlow, Helen Kalirai, Sarah E Coupland, Ronan Broderick, Samar Alsafadi, Alexandre Houy, Marc-Henri Stern, Stephen J Pettitt, Jyoti Sharma Choudhary, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Rachael Natrajan
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Nature genetics (2023)
Joseph S Baxter, Rachel Brough, Dragomir B Krastev, Feifei Song, Sandhya Sridhar, Aditi Gulati, John Alexander, Theodoros I Roumeliotis, Zuza Kozik, Jyoti S Choudhary, Syed Haider, Stephen J Pettitt, Andrew N J Tutt, Christopher J Lord
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7. Molecular oncology (2023)
Marta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, Jadwiga Nieminuszczy, John Alexander, Feifei Song, Malgorzata Dylewska, Ronan Broderick, Rachel Brough, Astrid Zimmermann, Frank T Zenke, Bora Gurel, Ruth Riisnaes, Ana Ferreira, Theodoros I Roumeliotis, Jyoti Sharma Choudhary, Stephen J Pettitt, Johann S de Bono, Andres Cervantes, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Irene Y Chong
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance. Cancer research 82 (21) (2022)
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J Pettitt, Krishna C Bulusu, Jenni Nikkilä, Zena Wilson, Adina M Hughes, Paul W G Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquín Arribas, Javier Cortes, Cristina Saura, Alan Lau, Susan E Critchlow, Brian Dougherty, Carlos Caldas, Gordon B Mills, J Carl Barrett, Josep V Forment, Elaine B Cadogan, Christopher J Lord, Cristina Cruz, Judith Balmaña, Lenka Oplustil O'Connor
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (20) (2022)
Dalia Tarantino, Callum Walker, Daniel Weekes, Helen Pemberton, Kathryn Davidson, Gonzalo Torga, Jessica Frankum, Ana M Mendes-Pereira, Cynthia Prince, Riccardo Ferro, Rachel Brough, Stephen J Pettitt, Christopher J Lord, Anita Grigoriadis, Andrew N J Tutt
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. Oncogene 41 (32) (2022)
Joseph S Baxter, Diana Zatreanu, Stephen J Pettitt, Christopher J Lord
Resistance to DNA repair inhibitors in cancer. Molecular oncology 16 (21) (2022)
Dragomir B Krastev, Shudong Li, Yilun Sun, Andrew J Wicks, Gwendoline Hoslett, Daniel Weekes, Luned M Badder, Eleanor G Knight, Rebecca Marlow, Mercedes Calvo Pardo, Lu Yu, Tanaji T Talele, Jiri Bartek, Jyoti Sharma Choudhary, Yves Pommier, Stephen J Pettitt, Andrew N J Tutt, Kristijan Ramadan, Christopher J Lord
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nature cell biology 24 (1) (2022)
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Lerin Geo, Diego Grande, Vera Grinkevich, Robert A Heald, Sophie Langdon, Jayesh Majithiya, Claire L McWhirter, Niall M B Martin, Shaun Moore, Joana Neves, Eeson Rajendra, Marco Ranzani, Theresia Schaedler, Martin Stockley, Kimberley Wiggins, Rachel Brough, Sandhya Sridhar, Aditi Gulati, Nan Shao, Luned M Badder, Daniela Novo, Eleanor G Knight, Rebecca Marlow, Syed Haider, Elsa Callen, Graeme Hewitt, Joost Schimmel, Remko Prevo, Christina Alli, Amanda Ferdinand, Cameron Bell, Peter Blencowe, Chris Bot, Mathew Calder, Mark Charles, Jayne Curry, Tennyson Ekwuru, Katherine Ewings, Wojciech Krajewski, Ellen MacDonald, Hollie McCarron, Leon Pang, Chris Pedder, Laurent Rigoreau, Martin E Swarbrick, Ed Wheatley, Simon Willis, Ai Ching Wong, Andre Nussenzweig, Marcel Tijsterman, Andrew Tutt, Simon J Boulton, Geoff S Higgins, Stephen J Pettitt, Graeme C M Smith, Christopher J Lord
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nature communications 12 (1) (2021)
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, George Seed, Alba Llop-Guevara, Diletta Bianchini, Pasquale Rescigno, Alec Paschalis, Claudia Bertan, Chloe Baker, Jane Goodall, Susana Miranda, Ruth Riisnaes, Ines Figueiredo, Ana Ferreira, Rita Pereira, Mateus Crespo, Bora Gurel, Daniel Nava Rodrigues, Stephen J Pettitt, Wei Yuan, Violeta Serra, Jan Rekowski, Christopher J Lord, Emma C Hall, Joaquin Mateo, Johann S de Bono
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer discovery 11 (11) (2021)
Roman M Chabanon, Daphné Morel, Thomas Eychenne, Léo Colmet-Daage, Ilirjana Bajrami, Nicolas Dorvault, Marlène Garrido, Cornelia Meisenberg, Andrew Lamb, Carine Ngo, Suzanna R Hopkins, Theodoros I Roumeliotis, Samuel Jouny, Clémence Hénon, Asuka Kawai-Kawachi, Clémence Astier, Asha Konde, Elaine Del Nery, Christophe Massard, Stephen J Pettitt, Raphaël Margueron, Jyoti S Choudhary, Geneviève Almouzni, Jean-Charles Soria, Eric Deutsch, Jessica A Downs, Christopher J Lord, Sophie Postel-Vinay
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer research 81 (11) (2021)
Dragomir B Krastev, Andrew J Wicks, Christopher J Lord
PARP Inhibitors - Trapped in a Toxic Love Affair. Cancer research 81 (22) (2021)
Roman M Chabanon, Mathieu Rouanne, Christopher J Lord, Jean-Charles Soria, Philippe Pasero, Sophie Postel-Vinay
Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature reviews. Cancer 21 (11) (2021)
Ilirjana Bajrami, Callum Walker, Dragomir B Krastev, Daniel Weekes, Feifei Song, Andrew J Wicks, John Alexander, Syed Haider, Rachel Brough, Stephen J Pettitt, Andrew N J Tutt, Christopher J Lord
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. Communications biology 4 (1) (2021)
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A Hancock, Jamin D Steffen, Ramya Billur, Zain M Hannan, Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt, Christopher J Lord, Tanaji T Talele, John M Pascal, Ben E Black
Structural basis for allosteric PARP-1 retention on DNA breaks. Science (New York, N.Y.) 368 (6486) (2020)
Stephen J Pettitt, Jessica R Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy Anthony Yap, Syed Haider, Andrew N J Tutt, Christopher J Lord
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer discovery 10 (10) (2020)
Christopher J Lord, Alan Ashworth
PARP inhibitors: Synthetic lethality in the clinic. Science (New York, N.Y.) 355 (6330) (2017)
Inger Brandsma, Emmy D G Fleuren, Chris T Williamson, Christopher J Lord
Directing the use of DDR kinase inhibitors in cancer treatment. Expert opinion on investigational drugs 26 (12) (2017)

Christopher J Lord.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christopher J Lord